Skip to main content
. Author manuscript; available in PMC: 2021 Mar 24.
Published in final edited form as: J Med Chem. 2020 Apr 22;63(10):5242–5256. doi: 10.1021/acs.jmedchem.0c00035

Figure 2.

Figure 2.

Design of three series of BRD4 inhibitors via a ligand structure-based drug design and scaffold hopping strategy. First panel: overlay of cocrystal structures of compounds 3 (in light blue, PDB code: 4MR4) and 7 (in pink, PDB code: 4MR3) with BRD4 BD1. Residues Asn140 and Tyr97 are labeled. Second panel: designed three series of novel compounds to explore the SAR.